Kaposi's sarcoma-associated herpesvirus

Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), is a type of herpesvirus that is linked with Kaposi's sarcoma, a type of cancer that forms masses in the skin, lymph nodes, or other organs. The virus is also associated with two other types of diseases: primary effusion lymphoma (PEL) and a form of Multicentric Castleman's disease (MCD).
Discovery[edit]
KSHV was first identified in 1994 by Yuan Chang and Patrick S. Moore, two researchers at the University of Pittsburgh. They discovered the virus in a sample of Kaposi's sarcoma tissue from a patient with AIDS. The discovery of KSHV has led to a better understanding of the pathogenesis of Kaposi's sarcoma and the other diseases associated with the virus.
Transmission[edit]
KSHV is transmitted through saliva. It can also be transmitted through sexual contact, organ transplantation, and from mother to child during birth. The virus is not highly contagious and is mostly found in certain populations, such as men who have sex with men, people from certain regions of Africa, and people with weakened immune systems.
Pathogenesis[edit]
After infection, KSHV can remain dormant in the body for a long time. However, when the immune system is weakened, the virus can reactivate and cause disease. KSHV infects the endothelial cells that line blood vessels and lymphatic vessels, as well as B cells, a type of white blood cell. The virus can cause these cells to proliferate and form tumors, leading to Kaposi's sarcoma.
Treatment[edit]
There is currently no cure for KSHV. However, antiviral drugs can help control the virus and prevent or treat diseases caused by KSHV. In addition, treatment of Kaposi's sarcoma often involves chemotherapy or radiation therapy.
See also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
